Weight-loss drugs: a healthy alternative?
Keywords:
GLP-1RA drugs, overweight, obesity.Abstract
Obesity is a major health issue globally. In Mexico, ENSANUT 2023 [1] reports that 37.1% of adults are affected, which greatly diminishes their quality of life. Presently, there are approved medications that aid in weight reduction. When these are used alongside a nutritious diet and consistent exercise, they provide an effective means of managing this condition, including the use of glucagon-like peptide-1 receptor agonists (GLP-1RA).
References
Barquera, S., Lucía Hernández-Barrera, Oviedo-Solís, C., Rodríguez-Ramírez, S., Monterrubio-Flores, E., Belem Trejo-Valdivia, Martínez-Tapia, B., Aguilar-Salinas, C., Galván-Valencia, O., Chávez-Manzanera, E., Rivera-Dommarco, J., & Campos-Nonato, I. (2024). Obesidad en adultos. Salud Pública de México, 66(4, jul-ago), 414–424. https://doi.org/10.21149/15863
Sagredo Pérez, Julio, and Gonzalo Allo Miguel. “Tratamiento farmacológico de la obesidad. Situación actual y nuevos tratamientos” [Pharmacological treatment of obesity. Current situation and new treatments]. Atención primaria 57(1), 103074. https://doi:10.1016/j.aprim.2024.103074
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMOA2032183/SUPPL_FILE/NEJMOA2032183_DATA-SHARING.PDF
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMOA1411892/SUPPL_FILE/NEJMOA1411892_DISCLOSURES.PDF
Martin, C. K., Carmichael, O. T., Carnell, S., Considine, R. V., Kareken, D. A., Dydak, U., Mattes, R. D., Scott, D., Shcherbinin, S., Nishiyama, H., Knights, A., Urva, S., Biernat, L., Pratt, E., Haupt, A., Mintun, M., Otero Svaldi, D., Milicevic, Z., & Coskun, T. (2025). Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature Medicine, 1–10. https://doi.org/10.1038/S41591-025-03774-9;SUBJMETA=1488,163,2743,378,393,631,692;KWRD=OBESITY
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242–1251. https://doi.org/10.1111/DOM.12932
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023). Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA, 330(18), 1795–1797. https://doi.org/10.1001/JAMA.2023.19574
Shor, R., Mihalache, A., Noori, A., Shor, R., Kohly, R. P., Popovic, M. M., & Muni, R. H. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology. https://doi.org/10.1001/JAMAOPHTHALMOL.2025.1455
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista de divulgación científica iBIO
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Self-archiving or deposit of the works in their post-publication version (editorial version) is permitted in any personal, institutional or thematic repository, social or scientific networks. The above applies from the moment of publication of the article in question on the website of the Revista de divulgación científica iBIO.
